Given the extensive lung involvement in the Fra-2 model compared to murine lupus (92), these findings suggest that CD19-targeted CAR-T cells may not be suitable for initial use in SSc patients with a high lung inflammatory burden. This evidence concerns the gene CD19 and systemic sclerosis.